Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

Published:2015-04-09 Issue:4 Volume:170 Page:445-456
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zhang Shuang Q.¹,Smith Sonali M.¹,Zhang Shuang Y.²,Lynn Wang Yue³

Affiliation:

1. Department of Medicine; Section of Haematology and Oncology; University of Chicago; Chicago IL USA

2. Department of Hematology and Oncology; Winship Cancer Institute; Emory University; Atlanta GA USA

3. Division of Genomic and Molecular Pathology; Department of Pathology; University of Chicago; Chicago IL USA

Funder

Leukemia and Lymphoma Society

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13427/fullpdf

Reference65 articles.

1. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;Journal of Clinical Oncology,2013

2. Ibrutinib and novel BTK inhibitors in clinical development;Akinleye;Journal of Hematology & Oncology,2013

3. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

4. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia;Amrein;Clinical Cancer Research,2011

5. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma;Boyd;Molecular & Cellular Proteomics: MCP,2009

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma;Medicine in Novel Technology and Devices;2024-06

2. Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review;BioNanoScience;2024-05-21

3. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

4. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma;Blood Advances;2023-07-14

5. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model;Clinical Cancer Research;2023-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3